Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 8:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,663 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Orlando, Florida Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Toric Soft Contact Lenses Containing a Chromophore to Block High-Energy Visible Light

NCT05344560
View directory record Official record
Conditions
Visual Acuity
Interventions
soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore, ACUVUE OASYS 1-Day for Astigmatism
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
10
States / cities
Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Jun 7, 2026, 8:39 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions
BIIB080, BIIB080-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 7, 2026, 8:39 AM EDT
Terminated Phase 2 Interventional

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

NCT06784973
View directory record Official record
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 5 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
41
States / cities
Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 3 Interventional Results available

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

NCT04305405
View directory record Official record
Conditions
Severe Uncontrolled Asthma
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Lincoln, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

NCT04003142
View directory record Official record
Conditions
Hot Flashes
Interventions
Fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
65
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Jun 7, 2026, 8:39 AM EDT
Recruiting Phase 2 Interventional

FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

NCT01466790
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, PSI-7977 (GS7977), Ribavirin
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
22
States / cities
Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

NCT04603027
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

NCT03605862
View directory record Official record
Conditions
Enterovirus, Rhinovirus
Interventions
Nitazoxanide, Placebo
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years and older
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Pelham, Alabama • Hot Springs, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Jun 7, 2026, 8:39 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141
View directory record Official record
Conditions
Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions
Perampanel Oral Suspension, Perampanel Tablet
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jun 7, 2026, 8:39 AM EDT
Recruiting Phase 2 Interventional

Ferric Citrate and Chronic Kidney Disease in Children

NCT04741646
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Ferric Citrate, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Years to 18 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 7, 2026, 8:39 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
391
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 3 Interventional Results available

18F-AV-1451 Autopsy Study

NCT02516046
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Los Gatos, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042
View directory record Official record
Conditions
Hepatic Impairment, Hepatic Function
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jun 7, 2026, 8:39 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT06137183
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Camarillo, California • Los Angeles, California • Mission Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 7, 2026, 8:39 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies
Interventions
Rapcabtagene autoleucel, Active Comparator Option
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
9
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT01631097
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Tivozanib hydrochloride
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Jun 7, 2026, 8:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

NCT07217886
View directory record Official record
Conditions
Renal Impairment
Interventions
S-892216-PO
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Orlando, Florida • St. Petersburg, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 2 Interventional

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254
View directory record Official record
Conditions
Venous Thrombosis
Interventions
PD 0348292, Enoxaparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Jun 7, 2026, 8:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

NCT04262791
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Wrist Actigraphy Device, Sleep Headband
Device
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Orlando, Florida • Grayslake, Illinois • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Jun 7, 2026, 8:39 AM EDT
Active, not recruiting Not applicable Interventional

STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad Tendon

NCT03935750
View directory record Official record
Conditions
Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability
Interventions
Anterior cruciate ligament reconstruction (ACLR), Lateral extra-articular tenodesis (LET)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 25 Years
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
14
States / cities
Redwood City, California • San Francisco, California • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jun 7, 2026, 8:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

NCT02143973
View directory record Official record
Conditions
Uremic Pruritus, Pruritus
Interventions
nalbuphine HCl ER
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jun 7, 2026, 8:39 AM EDT